Clinical-stage biotechnology company Antibe Therapeutics Inc (TSX:ATE) (OTCQX:ATBPF) announced on Thursday that it has received approval from Health Canada to initiate a pharmacokinetic/pharmacodynamic (PK/PD) study for otenaproxesul's faster-absorbing formulation for acute pain management.
This study is slated to begin in October and is designed to determine the dosages for the Phase II trial.
"With this approval, we're excited to start the first-in-human study of otenaproxesul's new formulation -- and to be on track to launch the Phase II trial in calendar Q1 2024," said Antibe CEO Dan Legault.
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial
Adcentrx's ADRX-0706 granted US FDA Fast Track designation to treat advanced cervical cancer
Ajinomoto and RIBOMIC announce successful extension of nucleic acid aptamer pharmacokinetics
AstraZeneca secures EU approval for Calquence combo as first-line treatment in mantle cell lymphoma
Odylia Therapeutics undertakes gene replacement therapy project for NPHP1 retinal dystrophy
Phanes Therapeutics doses first patient in peluntamig-atezolizumab combination clinical study